Shenyang Wosen Institute of Pharmacy

Main research purpose: Isradipine sustained-release capsules developed by Shenyang Watson Pharmaceutical Research Institute and Beijing Red Sun Pharmaceutical Co., Ltd. were used as the test preparation T, and DynaCirc SRO® produced by Novartis New Zealand Limited was used as the reference preparation R. Conduct a bioequivalence preliminary test under fasting conditions. Secondary study objectives: To evaluate the safety of isradipine extended-release capsules taken on an empty stomach in healthy Chinese subjects.

To study the pharmacokinetics of leuprolide acetate injection in healthy humans, explore the characteristics of drug absorption, distribution, metabolism and excretion in the human body, and clarify its pharmacokinetic characteristics, so as to provide a definite experimental basis for the design of clinical dosing regimen and dosage determination of leuprolide acetate injection, and provide a theoretical basis for the dosing regimen of Phase II clinical trials.

To evaluate the efficacy and safety of domestic leuprolide acetate immediate-release injection and leuprolide acetate sustained-release injection in the treatment of prostate cancer.